New pill challenges shot in fight against uncontrollable hives

NCT ID NCT06042478

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing if a new pill called remibrutinib can better control chronic hives in adults when standard allergy medicines don't work. It will compare the pill to a currently approved injection treatment (omalizumab) over one year, with an option for a second year on the pill. The main goal is to see which treatment is more effective at reducing itch and hives and is safe for long-term use.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

CABA, Buenos Aires, C1414AIF, Argentina
Novartis Investigative Site

Rosario, Santa Fe Province, 2000, Argentina
Novartis Investigative Site

Bahía Blanca, B8000JRB, Argentina
Novartis Investigative Site

CABA, C1012AAY, Argentina
Novartis Investigative Site

Capital Federal, C1023AAB, Argentina
Novartis Investigative Site

Mendoza, 5500, Argentina
Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, 90560-032, Brazil
Novartis Investigative Site

Alphaville Barueri, São Paulo, 06454-010, Brazil
Novartis Investigative Site

Santo André, São Paulo, 09060-870, Brazil
Novartis Investigative Site

Sorocaba, São Paulo, 18040-425, Brazil
Novartis Investigative Site

Sofia, 1421, Bulgaria
Novartis Investigative Site

Sofia, 1431, Bulgaria
Novartis Investigative Site

Varna, 9009, Bulgaria
Novartis Investigative Site

Edmonton, Alberta, T6G 1C3, Canada
Novartis Investigative Site

Hamilton, Ontario, L8L 3C3, Canada
Novartis Investigative Site

Hamilton, Ontario, L8S 1G5, Canada
Novartis Investigative Site

London, Ontario, N6H 5L5, Canada
Novartis Investigative Site

Niagara Falls, Ontario, L2H 1H5, Canada
Novartis Investigative Site

Québec, Quebec, G1V 4W2, Canada
Novartis Investigative Site

Verdun, Quebec, H4G 3E7, Canada
Novartis Investigative Site

Brno, 602 00, Czechia
Novartis Investigative Site

Plzen Bolevec, 32300, Czechia
Novartis Investigative Site

Prague, 100 34, Czechia
Novartis Investigative Site

Grenoble, 38043, France
Novartis Investigative Site

La Rochelle, 17019, France
Novartis Investigative Site

Nice, 06000, France
Novartis Investigative Site

Pierre-Bénite, 69495, France
Novartis Investigative Site

Rouen, 76031, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Munich, Bavaria, 81377, Germany
Novartis Investigative Site

Göttingen, Lower Saxony, 37075, Germany
Novartis Investigative Site

Stade, Lower Saxony, 21682, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Halle, Saxony-Anhalt, 06120, Germany
Novartis Investigative Site

Bad Bentheim, 48455, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Bochum, 44791, Germany
Novartis Investigative Site

Bochum, 44793, Germany
Novartis Investigative Site

Hamburg, 22391, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Lübeck, 23538, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

München, 80377, Germany
Novartis Investigative Site

Münster, 48149, Germany
Novartis Investigative Site

Osnabrück, 49074, Germany
Novartis Investigative Site

Tübingen, 72076, Germany
Novartis Investigative Site

Kaposvár, 7400, Hungary
Novartis Investigative Site

Ahmedabad, Gujarat, 380016, India
Novartis Investigative Site

Bangalore, Karnataka, 560004, India
Novartis Investigative Site

Belagavi, Karnataka, 590010, India
Novartis Investigative Site

Mysore, Karnataka, 570001, India
Novartis Investigative Site

Nagpur, Maharashtra, 440012, India
Novartis Investigative Site

Nagpur, Maharashtra, 440015, India
Novartis Investigative Site

Nashik, Maharashtra, 422101, India
Novartis Investigative Site

New Delhi, National Capital Territory of Delhi, 110029, India
Novartis Investigative Site

Bikaner, Rajasthan, 334003, India
Novartis Investigative Site

Hyderabad, Telangana, 500004, India
Novartis Investigative Site

Dehradun, Uttarakhand, 248001, India
Novartis Investigative Site

Milan, MI, 20122, Italy
Novartis Investigative Site

Rozzano, MI, 20089, Italy
Novartis Investigative Site

Modena, MO, 41124, Italy
Novartis Investigative Site

Roma, RM, 00186, Italy
Novartis Investigative Site

Siena, SI, 53100, Italy
Novartis Investigative Site

Muar town, Johor, 84000, Malaysia
Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, 50586, Malaysia
Novartis Investigative Site

Ipoh, Perak, 30450, Malaysia
Novartis Investigative Site

George Town, Pulau Pinang, 10450, Malaysia
Novartis Investigative Site

Petaling Jaya, Selangor, 46150, Malaysia
Novartis Investigative Site

Kuala Lumpur, 59100, Malaysia
Novartis Investigative Site

Wilayah Persekutuan, 62502, Malaysia
Novartis Investigative Site

Guadalajara, Jalisco, 44638, Mexico
Novartis Investigative Site

Cuauhtémoc, Mexico City, 06100, Mexico
Novartis Investigative Site

Villahermosa, Tabasco, 86035, Mexico
Novartis Investigative Site

Mérida, Yucatán, 97070, Mexico
Novartis Investigative Site

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site

Gdansk, 80-214, Poland
Novartis Investigative Site

Gdansk, 80-546, Poland
Novartis Investigative Site

Krosno, 38-400, Poland
Novartis Investigative Site

Poznan, 60-823, Poland
Novartis Investigative Site

Bardejov, 085 01, Slovakia
Novartis Investigative Site

Kežmarok, 060 01, Slovakia
Novartis Investigative Site

Svidník, 089 01, Slovakia
Novartis Investigative Site

Trnava, 917 02, Slovakia
Novartis Investigative Site

Ansan, Gyeonggi-do, 425-801, South Korea
Novartis Investigative Site

Busan, 49241, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Granada, Andalusia, 18014, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08003, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Las Palmas GC, 35010, Spain
Novartis Investigative Site

Valencia, 46015, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Zurich, 8091, Switzerland
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taoyuan District, 33305, Taiwan
Novartis Investigative Site

Songkhla, Hat Yai, 90110, Thailand
Novartis Investigative Site

Khon Kaen, THA, 40002, Thailand
Novartis Investigative Site

Bangkok, 10400, Thailand
Novartis Investigative Site

Bangkok, 10700, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Novartis Investigative Site

Sakarya, Adapazari, 54290, Turkey (Türkiye)
Novartis Investigative Site

Aydin, Efeler, 09100, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Fatih, 34093, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site

Denizli, Kinikli, 20070, Turkey (Türkiye)
Novartis Investigative Site

Birmingham, B9 5SS, United Kingdom
Novartis Investigative Site

Hanoi, 100000, Vietnam
Novartis Investigative Site

Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

CHRONIC SPONTANEOUS URTICARIA